Purpose: To compare the efficacy and safety of topical 0.1% indomethacin with 0.1% dexamethasone after cataract surgery. Methods: 145 patients (indo = 71, dexa = 74) were enrolled in a randomised, double-masked study and received one drop 4 times a day of indomethacin or dexamethasone for 1 month. Results: Proteinic flare and cellular Tyndall decreased with time in both groups, with a difference in favour of indomethacin for cellular Tyndall on day 30 (p = 0.046). Conjunctival hyperaemia was less pronounced in the dexamethasone group on day 30 (p = 0.03). Tolerance of both drugs was good. Conclusion: 0.1% Indomethacin solution appears to be as safe and efficient as 0.1% dexamethasone eyedrops in the management of post-operative inflammation and could be a good alternative to the use of steroids.

Keywords:
Cataract surgery, Inflammation, post-operative, Indomethacin, Dexamethasone
1.
Samiy N, Foster CS: The role of non-steroidal anti-inflammatory drugs in ocular inflammation. Int Ophthalmol Clin 1996;36(1):195–206.
2.
Flach AJ: Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 1992;6(4):259–283.
3.
Miyake K: Non-steroidal anti-inflammatory agents in cataract intraocular lens surgery. Curr Opin Ophthalmol 1995;6(1):62–65.
4.
Sourdille P, Zanlonghi X, Bron V, Allaire C, Trinquand C: Comparison of prednisolone and topical indomethacin in post-operative inflammation. Eur J Implant Refract Surg 1993;5:159–163.
5.
Colin J, Fardon T, Richard MC, Trinquand C, Roux M: A clinical comparison of two topical indomethacin formulations (0.1% solution versus 1% suspension) after cataract surgery. New Trends Ophthalmol 1993;3(1):5–9.
6.
Arnaud B, Trinquand C, and Study Group: Étude en double insu sur trois groupes parallèles de deux formulations d’indométacine à 0.1% et du diclofénac à 0.1% dans la prévention et le contrôle de l’inflammation après chirurgie de la cataracte. J Fr Ophtalmol 1997;20(3):183–188.
7.
Kraff MC, Sanders DR, McGuigan L, Raanan MG: Inhibition of blood-aqueous humor barrier breakdown with diclofenac: A fluorophotometric study. Arch Ophthalmol 1990;108:380–383.
8.
Flach AJ, Jaffe NS, Akers WA: The effect of ketorolac tromethamine in reducing post-operative inflammation: Double-mask comparison with dexamethasone. Ann Ophthalmol 1989;21:407–411.
9.
Ilic J, Gigon S, Leuenberger PM: Comparison of the anti-inflammatory effect of dexamethasone and diclofenac eyedrops (in French). Klin Monatsbl Augenheilkd 1984;184:494–498.
10.
Othenin-Girard P, Tritten J-J, Pittet N, Herbort CP: Dexamethasone versus diclofenac sodium eyedrops to treat inflammation after cataract surgery. J Cataract Refract Surg 1994;20:9–12.
11.
Roberts CW, Brennan KM: A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthalmol 1995;113:725–727.
12.
Demco TA, Sutton H, Demco CJ, Raj PS: Topical diclofenac sodium compared with prednisolone acetate after phacoemulsification-lens implant surgery. Eur J Ophthalmol 1997;7:236–240.
13.
Killer HE, Blumer B, Mayers M: Comparison of the anti-inflammatory potency and local tolerance of diclofenac and indomethacin eye drops in the postoperative management of patients undergoing ECCE with PCL. Ocul Immunol Inflamm 1993;1:211–217.
© 2001 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.